Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation.
PMID 19812689 · PMC2753653 · PloS one · 2009 · 7 claims · 5 setups
Natural CTL immunodominance toward variable proteome regions increases epitope mismatch with challenge strains and recapitulates the escape-driven CTL failure seen in natural infection, contributing to HIV vaccine failure
-
Full-text index only
Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines.
PMID 41811958 · PMC12978219 · Science advances · 2026 · 6 claims · 7 setups
An integrated pipeline combining ML-based epitope prediction (netMHCpan, EpiDope, BepiPred), TCRpMHC structural modeling/docking, and JessEV vaccine design can prioritize viral peptides by immunogenicity, allele coverage, solubility, and stability.
-
Full-text index only
Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.
PMID 19918099 · PMC4155129 · Antiviral therapy · 2009 · 8 claims · 6 setups
Primary integrase inhibitor resistance mutations (T66I, E92Q, G140S, Y143C/H/R, Q148H/R/K, N155S/H) were absent in 342 drug-naive individuals, indicating these sites are highly constrained.
-
Full-text index only
Evidence for a novel gene associated with human influenza A viruses.
PMID 19917120 · PMC2780412 · Virology journal · 2009 · 8 claims · 8 setups
A 167-codon ORF (NEG8) on the negative-sense genomic strand of segment 8 is associated with early-20th-century human influenza A isolates
-
Full-text index only
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.
PMID 19969118 · PMC2821965 · Vaccine · 2010 · 7 claims · 8 setups
rMVA expressing multiple antigens under the mH5 promoter exhibit remarkable genetic stability and maintain potent immunogenicity after serial passage